A new milestone achieved in BARBICAN Study!
20 Spanish patients have been successfully randomized in the study, reaching 50% recruitment in Spain.
The last patient to be randomized by Dr. Stradella and her team from ICO Hospitalet on 7th October 2019 and have started treatment.
The BARBICAN study compares the addition of ipatasertib to atezolizumab plus neoadjuvant chemotherapy in patients with triple-negative breast cancer.
The primary clinical endpoint is to compare pCR rates in the two treatment arms and determine whether adding the AKT-inhibitor ipatasertib to atezolizumab and chemotherapy increases the probability of an immune response over adding atezolizumab alone.
In addition, a biological co-primary endpoint would determine whether adding the AKT-inhibitor ipatasertib to atezolizumab and chemotherapy increases the probability of immune response over adding atezolizumab to chemotherapy in all treated patients.
Globally, the trial will enroll a total of 142 patients in three countries, (UK, Germany, and Spain) with an estimated accrual period of 12 months.
We would like to thank all the study teams for their interest and commitment in the study, especially top recruiters in Hospital Clínico de Valencia (Dr. Begoña Bermejo), Hospital Virgen del Rocío (Dr. Javier Salvador) and ICO Hospitalet (Dr. Agostina Stradella). Together we can do more!
Author: Francisco Roldán